Financial Statements
For the three months ended September 30, 2019 and 2018
(Expressed in Canadian Dollars)

## **NOTICE TO READER**

Under National Instrument 51-102 "Continuous Disclosure Requirements", Part 4, Subsection 4.3(3)(a), if an auditor has not performed a review of the unaudited interim financial statements, they must be accompanied by a notice indicating that the unaudited interim financial statements have not been reviewed by an auditor.

The accompanying unaudited interim financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these unaudited interim financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

Condensed Interim Statements of Financial Position (Expressed in Canadian Dollars) (Unaudited)

	Se	ptember 30, 2019		June 30, 2019
Assets				
Current				
Cash	\$	1,859,219	\$	1,216,210
Receivables		72,069		28,277
Subscriptions receivable (note 5)		17,500		31,000
Prepaid expenses and deposits		428,551		163,792
		2,377,339		1,439,279
Deferred financing costs (note 11)		22,500		22,500
iabilities		1,376,450		1,451,060
		1,398,950		1,473,560
	\$	3,776,289	\$	2,912,839
Current Accounts payable and accrued liabilities (note 7) Obligation to issue shares (note 4)	\$	536,766 316,220	\$	308,873 316,220
Obligation to issue shares (note 4)		852,986		625,093
Shareholders' Equity		032,900		025,095
Common shares (note 5)		4,102,563		1,675,400
Common share subscriptions (note 5)		297,500		1,179,163
Reserves		51,270		-
Deficit		(1,528,030)		(566,817)
		2,923,303		2,287,746
	\$	3,776,289	\$	2,912,839
Approved on behalf of the Board:				
"Kal Malhi" (signed)	"Rol	bert Delamar" (	(signe	ed)
Director The accompanying notes are an integral part of these	condensed i	Director nterim financia	ıl stat	ements.

Condensed Interim Statements of Comprehensive Loss (Expressed in Canadian Dollars) (Unaudited)

	Three mon	Three months ended			
	September 30, 2019		September 30, 2018		
Operating expenses					
Accounting and audit fees	\$ 6,000	\$	7,500		
Advertising and promotions	134,872		-		
Advisory fees	56,555		-		
Amortization (note 4)	74,610		-		
Interest and bank charges	1,791		225		
Investor relations	63,830		-		
Legal fees	2,777		9,377		
Management fees (note 7)	166,109		57,999		
Office and general expenses	11,043		-		
Patents and licensing expenses (note 4)	1,720		950		
Regulatory filing fees	15,169		-		
Rent	7,000		-		
Research and development (note 6)	366,912		-		
Share based compensation	51,270		-		
	(959,658)		(76,051)		
Other items					
Foreign exchange loss	(1,555)		-		
Net loss and comprehensive loss for the period	\$ (961,213)	\$	(76,051)		
Basic and diluted loss per share	\$ (0.03)	\$	(0.01)		
Weighted average number of common shares outstanding	38,002,988		9,152,002		

The accompanying notes are an integral part of these condensed interim financial statements.

Condensed Interim Statement of Changes in Equity (Expressed in Canadian Dollars) (Unaudited)

	Common Shares					
	Number	Amount	Subscriptions	Reserves	Deficit	<b>Total Equity</b>
	Outstanding	\$	\$	\$	\$	\$
Balance, June 30, 2018	100	100	447,750	-	(45,866)	401,984
Private placements (note 5)	9,810,000	490,500		-		490,500
Share issuance costs	-	(23,075)		-		(23,075)
Common share subscriptions	-	-	(463,750)	-	-	(463,750)
Net loss for the period	-	-	-	-	(76,051)	(76,051)
Balance, September 30, 2018	9,810,100	467,525	(16,000)		(121,917)	329,608
Balance, June 30, 2019	34,277,600	1,675,400	1,179,163	-	(566,817)	2,287,746
Private placements (note 5)	6,977,610	2,442,163	(1,179,163)	-	-	1,263,000
Cancelled shares	(300,000)	(15,000)				(15,000)
Common share subscriptions (note 11)	-	-	297,500	-	-	297,500
Share-based compensation	-	-	-	51,270	-	51,270
Net loss for the period	<u>-</u>		<u>-</u>	<u>-</u>	(961,213)	(961,213)
Balance, September 30, 2019	40,955,210	4,102,563	297,500	51,270	(1,528,030)	2,923,303

The accompanying notes are an integral part of these condensed interim financial statements.

Condensed Interim Statements of Cash Flows (Expressed in Canadian Dollars) (Unaudited)

	Se	Three mor ptember 30, 2019	ended ptember 30, 2018			
Operating activities						
Net loss for the period	\$	(961,213)	\$	(76,051)		
Items not affecting cash:						
Amortization		74,610		-		
Foreign exchange loss		1,555		-		
Share based compensation		51,270		-		
Change in working capital balances:						
Receivables		(43,792)		(6,223)		
Prepaid expenses and deposits		(264,759)		-		
Accounts payable and accrued liabilities	226,338			68,164		
Cash used in operating activities		(915,991)		(14,110)		
Financing activities						
Common shares issued, net of share issue costs		2,440,663		467,425		
Common share subscriptions (notes 5 and 11)		(881,663)		(463,750)		
Cash provided by financing activities		1,559,000		3,675		
Inflow (outflow) of cash		643,009		(10,435)		
Cash, beginning of period		1,216,210		440,565		
Cash, end of period	\$	1,859,219	\$	430,130		
Supplemental Cash Flow Information						
Share issues included in subscriptions receivable	\$	17,500	\$	_		
Interest paid	\$	, 5 3 5	\$	-		
Taxes paid	\$	_	\$	_		

There were no cash investing activities during the three months ended September 30, 2019 and 2018.

The accompanying notes are an integral part of these condensed interim financial statements.

Notes to the Condensed Interim Financial Statements For the Three Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

#### 1. NATURE OF OPERATIONS AND GOING CONCERN

First Responder Technologies Inc. (the "Company") was incorporated under the *BC Business Corporations Act* on January 27, 2017. The Company is a technology development company that commercializes academic and internally developed intellectual property for the purpose of developing new products for use in the public safety market. The principal business of the Company is the development of detection products and services that empower first responders to react effectively and efficiently in emergencies.

The Company has two areas of product development focus:

- (i) Detection which involves commercializing a new threat detection technology based on academic research developed by Rutgers, The State University of New Jersey ("Rutgers"), and ongoing research and development efforts by its in-house and outsourced development team; and
- (ii) Response which involves commercializing a less harmful pepper spray and antidote developed by the National Institutes of Health ("NIH").

The Company's registered and records office address is 1500 – 1055 West Georgia Street, Vancouver, BC, V6E 4N7. Its principal place of business is 915 – 700 West Pender Street, Vancouver, BC, V6C 1G8.

These condensed interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. At present, the Company has no current operating income. As at September 30, 2019, the Company has a deficit of \$1,528,030 (June 30, 2019 – \$566,817) and for the three months then ended, incurred a net loss of \$961,213 (2018 – \$76,051). Without additional financing, the Company may not be able to fund its ongoing operations and complete development activities. The Company intends to finance its future requirements through a combination of debt and/or equity issuance. There is no assurance that the Company will be able to obtain such financings or obtain them on favorable terms. These uncertainties may cast significant doubt on the Company's ability to continue as a going concern. The Company will need to raise sufficient working capital to maintain operations. These financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

## 2. BASIS OF PRESENTATION

#### (a) Statement of compliance

These unaudited condensed interim financial statements were prepared in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting using accounting policies consistent with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"). These condensed interim financial statements do not include all of the information required for full annual financial statements. These condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended June 30, 2018.

In preparing these condensed consolidated interim financial statements, the significant accounting policies and the significant judgments made by management in applying the Company's significant accounting policies and key sources of estimation uncertainty were the same as those that applied to the Company's audited financial statements for the year ended June 30, 2018.

These financial statements are presented in Canadian dollars, which is the Company's functional currency.

Notes to the Condensed Interim Financial Statements For the Three Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

## (b) Basis of presentation

These condensed interim financial statements have been prepared on a historical cost basis, except for certain financial instruments classified as financial instruments at fair value through profit or loss, which are stated at fair value. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

### (c) Approval of the financial statements

These condensed interim financial statements were authorized for issue by the Audit Committee and Board of Directors on November 27, 2019.

#### 3. SIGNIFICANT ACCOUNTING POLICIES

#### (a) Use of estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may vary from these estimates.

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Accounting estimates will, by definition, seldom equal the actual results. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future years affected.

Critical accounting estimates and assumptions made by management include, but are not limited to, the following:

#### Recoverability of asset carrying values

Determining the amount of impairment of intangible assets requires an estimation of the recoverable amount, which is defined as the higher of fair value less the cost of disposal or value in use. Many factors used in assessing recoverable amounts are outside of the control of management and it is reasonably likely that assumptions and estimates will change from period to period.

## Useful lives of intangible assets

Amortization is recorded on the straight-line basis based upon management's estimate of the useful life and residual value. The estimates are reviewed at least annually and are updated if expectations change as a result of the technical obsolescence or legal and other limits to use. A change in the useful life or residual value will impact the reported carrying value of the intangible assets resulting in a change in related amortization expense.

Significant areas requiring the use of management's judgments include:

## Going concern

The assessment of whether the concern assumption is appropriate requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the

Notes to the Condensed Interim Financial Statements For the Three Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

end of the reporting period. The Company is aware that material uncertainties exist related to events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern.

### Treatment of development costs

Costs to develop products are capitalized to the extent that the criteria for recognition as intangible assets in IAS 38 *Intangible Assets* are met. Those criteria require that the product is technically and economically feasible, which management assessed based on the attributes of the development project, perceived user needs, industry trends and expected future economic conditions. Management considers these factors in aggregate and applies significant judgment to determine whether the product is feasible. The Company has not capitalized any development costs as at June 30, 2019.

#### Treatment of deferred financing costs

Professional, consulting, regulatory and other costs directly attributable to financing transactions are recorded as deferred financing costs until the financing transactions are completed, if the completion of the transaction is considered likely; otherwise they are expensed as incurred. Management applies significant judgment to determine whether the completion of the transaction is considered likely.

## Treatment of acquired intangible assets

Consideration paid in the acquisition of intangible assets is capitalized to the extent that the definition of an intangible asset and the criteria for recognition as intangible assets in IAS 38 *Intangible Assets* are met. Those criteria require that the intangible asset be identifiable, the Company must have control over it, and it must provide future economic benefits. Management considers these factors in aggregate and applies significant judgment to determine whether the intangible asset should be recognized in the statements of financial position.

#### Recoverability of intangible assets

The Company assesses at each reporting date if intangibles assets have indicators of impairment. In determining whether intangible assets are impaired, the Company assesses certain criteria including observable decreases in value, significant changes with adverse effect on the entity, a change in market interest rates, evidence of technological obsolescence, and future plans.

#### Recoverability of deferred tax assets

The measurement of income taxes payable and deferred income tax assets and liabilities requires management to make judgments in the interpretation and application of the relevant tax laws. The actual amount of income taxes only becomes final upon filing and acceptance of the tax return by the relevant tax authorities, which occurs subsequent to the issuance of the financial statements.

#### 4. INTANGIBLE ASSETS

## (a) The National Cancer Institute and the National Institutes of Health ("NIH")

On February 18, 2019, the Company entered into a license assignment agreement with Bullrun Capital (the "NIH License Assignment Agreement"), pursuant to which Bullrun Capital assigned to the Company all rights, titles and interests contemplated in the NIH License Agreement. As a result, the Company, through the NIH License Assignment Agreement, holds the nonexclusive worldwide rights for the new pepper spray formulation technology.

Notes to the Condensed Interim Financial Statements For the Three Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

(b) Rutgers, The State University of New Jersey, The Research Foundation for the State of University of New York, acting for and on behalf of Binghamton University, and the Trustees of Indiana University (collectively "Rutgers" or the "Licensors")

On June 28, 2019, the Company entered into a license assignment agreement with Bullrun Capital (the "Rutgers License Assignment Agreement"), pursuant to which Bullrun Capital assigned to the Company all rights, titles and interests contemplated in the Rutgers License Agreement. As a result, the Company, through the Rutgers License Assignment Agreement, holds the exclusive global rights for the new WiFi technology.

As disclosed in note 11, on November 19, 2019, The Company filed its final long-form prospectus offering a minimum of 10,000,000 Units and a maximum of 20,000,000 Units at \$0.35 per Unit as an initial public offering. As such, the Company determined that it is likely the initial public offering will be completed and recorded an obligation to issue shares of \$316,220 which was capitalized to intangible assets. This amount was determined based on an estimated 6,324,401 common shares with a fair value of \$0.05 per share to be issued to Rutgers, representing 10% of the estimated shares outstanding on a fully-diluted basis following the minimum expected initial public offering.

	NIH License Assignment Agreement	Rutgers License Assignment Agreement	Total
Cost			
Balance, June 30, 2019 Additions	\$ 608,972	\$ 882,688	\$ 1,491,660 -
Balance, September 30, 2019	\$ 608,972	\$ 882,688	\$ 1,491,660
Accumulated Amortization			
Balance, June 30, 2019	\$ 40,600	\$ -	\$ 40,600
Amortization	30,450	44,160	74,610
Balance, September 30, 2019	\$ 71,050	\$ 44,160	\$ 115,210
Cost			
Balance, June 30, 2018	\$ -	\$ -	\$ -
Additions	608,972	882,688	1,491,660
Balance, June 30, 2019	\$ 608,972	\$ 882,688	\$ 1,491,660
Accumulated Amortization			
Balance, June 30, 2018	\$ -	\$ -	\$ -
Amortization	40,600	-	40,600
Balance, June 30, 2019	\$ 40,600	\$ -	\$ 40,600
Carrying Amounts			
September 30, 2019	\$ 537,922	\$ 838,528	\$ 1,376,450
June 30, 2019	\$ 568,372	\$ 882,688	\$ 1,451,060

Notes to the Condensed Interim Financial Statements For the Three Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

### 5. SHAREHOLDERS' EQUITY

#### (a) Authorized

Unlimited number of common shares without par value.

#### (b) Issued and outstanding

## Three months ended September 30, 2018

On July 5, 2018, the Company completed the first tranche of a non-brokered private placement financing (the "July 2018 Private Placement") raising aggregate gross proceeds of \$460,250 through the issuance of 9,205,000 common shares at \$0.05 per share.

On July 24, 2018, the Company completed the second tranche of the July 2018 Private Placement raising aggregate gross proceeds of \$30,250 through the issuance of 605,000 common shares at \$0.05 per share. Associated with the July 2018 Private Placement, the Company incurred share issue costs of \$23,075.

## Three months ended September 30, 2019

On August 9, 2019, the Company completed a non-brokered private placement of 6,977,610 units at a price of \$0.35 per unit for gross proceeds of \$2,442,164. Each unit consists of one common share and one half common share purchase warrant entitling the holder to purchase one additional common share at an exercise price of \$0.50 per common share for a full warrant for two years from the date of issue.

#### (c) Common share purchase warrants

As at September 30, 2019 and June 30, 2019, the Company had the following warrants outstanding:

	Sep	tember 30, 20	June 30, 2019			
Expiry date	Number of warrants	Exercise Price	Remaining life (years)	Number of warrants	Exercise price	Remaining life (years)
August 9, 2021	3,488,802	\$0.50	1.86	-	-	-
	32,674,704	\$0.50	1.86	-	-	-

## Warrant activity was as follows:

	Number of warrants	Exercise price
Balance at June 30, 2019 and 2018	-	-
Issued	3,488,802	\$0.50
Balance at September 30, 2019	3,488,802	\$0.50

Notes to the Condensed Interim Financial Statements For the Three Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

## (d) Stock options

Issued

Balance at September 30, 2019

On July 11, 2019, the Company implemented an Incentive Stock Option Plan (the "Plan"). Pursuant to the Plan, the Company will grant stock options to directors, officers, employees and consultants for services, provided that the number of common shares reserved for issuance shall not exceed 10% of the issued and outstanding common shares exercisable for a period of up to 5 years. The exercise price and vesting terms of the options granted under the Plan will be determined by the Board of Directors.

As at September 30, 2019 and June 30, 2019, the Company had the following options outstanding:

	Sep	tember 30, 20	19	June 30, 2019			
Expiry date	Number of options	Exercise Price	Remaining life (years)	Number of options	Exercise price	Remaining life (years)	
July 25, 2024	3,000,000	\$0.05	4.82	-	-	-	
	3,000,000	\$0.05	4.82	-	-	_	
ption activity wa	as as follows:						
				Numb optio		Exercise price	
Balance at June	30, 2019 and 201	8			-	-	

The Company used the Black-Scholes option pricing model to determine the fair value of 3,000,000 options granted for the three months ended September 30, 2019 with a weighted average fair value of \$0.03. The following weighted average assumptions were used:

3,000,000

3,000,000

	2019
Risk-free interest rate	1.43%
Expected dividend yield	0.00%
Expected stock price volatility	100%
Expected option life in years	5.00
Forfeiture rate	0.00%

During the three months ended September 30, 2019, the Company recorded \$51,270 (2018 – \$nil) in relation to the vesting of the stock options.

\$0.05

\$0.05

Notes to the Condensed Interim Financial Statements For the Three Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

#### 6. RESEARCH AND DEVELOPMENT

Details of research and development expenses during the three months ended September 30, 2019 and 2018 are as follows:

		nths end	s ended	
Pepper spray formulation technology WiFi-based weapons detection technology Other	Sep	tember 30, 2019	•	mber 30, 018
	\$	28,374 338,538	\$	- -
	\$	366,912	\$	-

#### 7. RELATED PARTY TRANSACTIONS

The Company's related parties consist of key management personnel and companies owned directly or indirectly by key management personnel.

Key management personnel include persons having the authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Board of Directors and corporate officers.

During the three months ended September 30, 2019, the Company incurred management fees of \$121,109 (2018 – \$21,999) to the Company's key management personnel.

During the three months ended September 30, 2019, the Company incurred management fees of \$45,000 (2018 – \$36,000) to companies owned directly or indirectly by key management personnel of the Company.

As at September 30, 2019, accounts payable and accrued liabilities includes \$15,750 (June 30, 2019 – \$3,500) payable to key management personnel and companies owned directly or indirectly by key management personnel.

Amounts due to related parties included in accounts payable and accrued liabilities are unsecured, non-interest-bearing and are without fixed terms of repayment.

## 8. RISK MANAGEMENT

#### (a) Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Credit risk for the Company is associated with its cash. The Company is not exposed to significant credit risk as its cash is placed with a major Canadian financial institution.

## (b) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company is not exposed to significant liquidity risk.

Notes to the Condensed Interim Financial Statements For the Three Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

As at September 30, 2019, the Company had a cash balance of \$1,859,219 (June 30, 2019 – \$1,216,210) available to apply against short-term business requirements and current liabilities of \$852,986 (June 30, 2019 – \$625,093). All of the liabilities presented as accounts payable and accrued liabilities are due within 90 days of September 30, 2019.

#### (c) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk comprises three types of risk: foreign currency risk, interest rate risk and other price risk. The Company is not exposed to significant market risk.

#### 9. CAPITAL MANAGEMENT

The Company has just commenced operations. It has not yet determined whether it will be successful in its endeavours and does not generate cash flows from operations. The Company's primary source of funds comes from the issuance of common shares. The Company does not use other sources of financing that require fixed payments of interest and principal due to lack of cash flow from current operations and is not subject to any externally imposed capital requirements.

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern.

The Company defines its capital as shareholders' equity. Capital requirements are driven by the Company's general operations. To effectively manage the Company's capital requirements, the Company monitors expenses and overhead to ensure costs and commitments are being paid.

## 10. SEGMENTED INFORMATION

The Company has one operating segment, technology development. All assets of the Company are located in Canada.

#### 11. EVENTS AFTER THE REPORTING DATE

On November 19, 2019, The Company filed its final long-form prospectus with the securities regulatory authorities in the Provinces of Ontario, Alberta and British Columbia and with the Canadian Securities Exchange (the "CSE"), offering a minimum of 10,000,000 Units and a maximum of 20,000,000 Units at \$0.35 per Unit as an initial public offering (the "Offering"). Each Unit consists of one common share and one-half of one common share purchase warrant. Each whole common share purchase warrant entitles the holder to purchase one common share of the Company at \$0.50 per share for a period of 24 months from the completion of the Offering. Pursuant to an Agency Agreement between the Company and PI Financial Corp. (the "Agent"), the Agent will receive a cash commission equal to 8% of the gross proceeds, be paid a corporate finance fee of \$25,000, be reimbursed for reasonable expenses, and will be granted non-transferable agent warrants equal to 8% of the Units sold in the Offering to purchase common shares at a price of \$0.50 per common share, exercisable for a period of 24 months from the date the common shares commence trading on the CSE. The Agent will also be reimbursed by the Company for the Agent's expenses, including legal fees, incurred pursuant to the Offering. As at September 30, 2019 and June 30, 2019, included in deferred financing costs is an amount of \$22,500 paid to the Agent.